Akums Drugs and Pharmaceuticals IPO Subscription Status

Akums Drugs and Pharmaceuticals IPO Subscription - Day-3 Subscription at 63.44 times

Akums Drugs and Pharmaceuticals IPO closed on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE, NSE. As of 1 Aug 2024, Akums Drugs and Pharmaceuticals IPO received bids for 96,18,57,204 shares much more than the 1,51,62,239 shares offered. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed 63.44 times by the end of day 3.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 3 (1 August 2024 at 6:16 pm): 

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by QIB investors on day 3, followed by High NetWorth Individuals and Non Institutional Investors (NIIs), while retail investors showed less interest on day 3. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market making segment of the IPO. 

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Subscription Status of Akums Drugs and Pharmaceuticals IPO for Days 1, 2, and 3

On day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. By day 2, the subscription status had risen to 4.46 times and on day 3, it reached 63.44 times.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 3:

Data Source: NSE

For Akums Drugs and Pharmaceuticals IPO Qualified Institutional Buyers (QIBs) showed good interest on day 3 and subscribed 90.09 times. HNIs / NIIs portion subscribed 42.10 times while Retail Investors subscribed 20.80 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 63.44 times on Day 3

Akums Drugs and Pharmaceuticals IPO - Day 2 Subscription at 4.45 Times

Akums Drugs and Pharmaceuticals IPO will close on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE, NSE. By 31 July 2024, Akums Drugs and Pharmaceuticals IPO received bids for 6,74,40,450 shares much more than the 1,51,62,239 shares available. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed by 4.45  times by the end of day 2.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 2 (31st July 2024 at 5:59 pm):

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by retail investors on day 2, followed by High NetWorth Individuals and Non Institutional Investors (NIIs), at last Qualified Institutional Buyers (QIBs) showed less interest on day 2. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market making segment of the IPO. 

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 2:

Data Source: NSE

On day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. By day 2, the subscription status had risen to 4.45 times. Qualified Institutional Buyers (QIBs) did not show much interest on day 2 and subscribed 0.96 times. HNIs / NIIs portion subscribed 8.49 times while Retail Investors subscribed 9.05 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 4.45 times on Day 2

Akums Drugs and Pharmaceuticals IPO - Day 1 Subscription at 1.39 Times

Akums Drugs and Pharmaceuticals IPO will close on 1 Aug. Shares of Akums Drugs and Pharmaceuticals are likely to be listed on 6 August on BSE and NSE.

On 30 July 2024, Akums Drugs and Pharmaceuticals IPO received bids for 2,11,10,606 shares, much more than the 1,51,62,239 shares available. It means Akums Drugs and Pharmaceuticals IPO was oversubscribed by 1.39 times by the end of Day 1.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO as of Day 1:

Akums Drugs and Pharmaceuticals IPO subscription was mainly driven by retail investors on Day 1, followed by High Net Worth Individuals and Non-Institutional Investors (NIIs), with Qualified Institutional Buyers (QIBs) showing less interest on Day 1. QIBs and HNIs/NIIs generally increase their subscriptions in the final hours of the last day. Overall subscription figures do not include the anchor portion or the market-making segment of the IPO.

QIBs are large institutional investors like mutual funds and insurance companies, while HNIs/NIIs are wealthy individual investors and smaller institutions.

Here are the subscription details for Akums Drugs and Pharmaceuticals IPO by category as of Day 1:

Data Source: NSE

On Day 1, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times. Qualified Institutional Buyers (QIBs) did not show much interest on Day 1 and subscribed 0.43 times. HNIs / NIIs portion subscribed 1.97 times while Retail Investors subscribed 3.46 times. Overall, Akums Drugs and Pharmaceuticals IPO was subscribed 1.39 times.

About Akums Drugs and Pharmaceuticals Ltd

Founded in 2004, Akums Drugs and Pharmaceuticals Limited is a top pharmaceutical contract development and manufacturing organization (CDMO). They offer product development, manufacturing, R&D, regulatory dossier preparation, and testing services, producing and selling branded drugs and APIs.

Akums manufactures various dosage forms, serving 26 of the top 30 Indian pharmaceutical companies in 2023. With 10 manufacturing units and a capacity of 49.21 billion units annually, they plan to add two more units by FY 2025. Their facilities are accredited by EU-GMP, WHO-GMP, and US NSF.

Highlights of Akums Drugs and Pharmaceuticals IPO:

IPO Price Band: ₹646 to ₹679 per share.

Minimum Application Lot Size: 22 shares.

Minimum Investment for Retail Investors: ₹14,938.

Minimum Investment for High Net-worth Investors (HNI): 14 lots (308 shares), ₹209,132.

Registrar: Link Intime India Private Ltd.

Akums Drugs and Pharmaceutical will utilize the net proceeds towards repayment or prepayment of the company's and its subsidiaries’ debts, supporting the company's working capital needs and covering general corporate expenses.